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Biomarkers complement clinical assessment and the 12-lead ECG in the diagnosis, risk stratification, triage, and management of patients with
suspected acute coronary syndrome(ACS).While there is broadconsensus that cardiac troponin (cTn) I orT is thepreferredbiomarker in clinical
practice, important uncertainties remain regarding the value of high-sensitivity cTn assays, their best clinical use including the most appropriate
timing of serial measurements, aswell as the added value of other biomarkers reflecting and quantifying other pathophysiological signals including
copeptin and natriuretic peptides. This review will address these aspects with a focus on the diagnostic application of biomarkers, as they are
associated with immediate therapeutic consequences. In addition, this review will briefly highlight that increased diagnostic accuracy offered
by high-sensitivity cTn assays has contributed to improve our understanding of the incidence, pathophysiology, and mortality of the two distinct
components currently summarized under the term ACS: acute myocardial infarction and unstable angina.
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Introduction
The two components of the acute coronary syndromes (ACS), acute
myocardial infarction (AMI) and unstable angina (UA), are major
causes of death and disability worldwide.1–3 The risk of death and
the benefit from early revascularization are highest within the first
hours; therefore early diagnosis is critical.1 –4
Approximately 15–20 million patients per year present to the
emergency department (ED) with acute chest pain or other symp-
toms suggestive of ACS in Europe and the USA. As about two-thirds
of these patients will be found not to have ACS, rule-in and rule-out
seem to be equally important.1–4
Current standard of care
Biomarkers complement clinical assessment and the 12-lead ECG in
the diagnosis, risk stratification, triage, and management of patients
with suspected ACS. While both clinical assessment including a
detailed evaluation of chest pain characteristics and the 12-lead
ECG are indispensable tools, on their own, they have insufficient ac-
curacy. Therefore,measurement of a biomarker reflecting and quan-
tifying cardiomyocyte injury, preferably cardiac troponin (cTn) I or T,
is mandatory in all patients presenting with suspected ACS. The uni-
versal definition of myocardial infarction, which is supported by the
European Society of Cardiology, the American Heart Association,
the American College of Cardiology, and the World Heart Feder-
ation, since 2000 has defined the 99th percentile of healthy indivi-
duals as the cTn decision value for AMI.3 Despite this, many
institutions worldwide ignore this guideline and continue to use
highercut-off values for cTn.4This is ofmajorconcern, as this practice
incorrectly assigns patients with small AMIs or patients with large
AMIs presenting early ‘normal’ cTn levels and thereby contributes
to misdiagnosis and ultimately harms patients.1–4
Particularly when discussing the clinical value of biomarkers, it is
important to reiterate that ACS includes two distinct clinical entities,
AMI (ischaemic chest pain at rest with cardiomyocyte necrosis) and
UA (ischaemic chest pain at rest or minimal exertion without cardi-
omyocyte necrosis), that differ substantially in their risk to the patient
and the documented benefit of early revascularization.1–3
Cardiac troponin
Cardiac troponin I and T are proteins unique to the heart and spec-
ific and sensitive biomarkers of myocardial damage.2–4 The cTn
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complex is immobilized on the thin filament of the contractile
apparatus and plays a critical role in the regulation of excitation–
contraction coupling in the heart.1–3 In AMI, cTnI and cTnT are
released from necrotic myocardium both as intact proteins and deg-
radationproducts.Detectionof cTn inperipheral blood indicates and
quantifies cardiomyocyte damage.Amajor limitationof conventional
cTn assays is their low sensitivity at the time of patient presentation,
owing to a delayed increase in circulating levels requiring serial
sampling for 6–9 h in a significant number of patients.1–6
Sensitive and high-sensitivity
cardiac troponin assays, and the
99th percentile
Recent advances in assay technology have lead to a refinement in cTn
assays and therefore the clinical ability to detect and quantify cardio-
myocyte injury.1–4 Sensitive (detection of cTn in 20–50% of
healthy individuals) and high-sensitivity cTn (hs-cTn, detection of
cTn in50–90% of healthy individuals) assays have two differentiat-
ing features from conventional cTn assays: (i) detection of cTn in a
substantial number of healthy persons and (ii) a more precise defin-
itionofwhat is ‘normal’ (¼ the99thpercentile)with aprecisionof the
assay expressed as the coefficient of variability which should be
,20% and preferably ,10%.1–24 These features are of key import-
ance as a cTn value above the 99th percentile of a normal reference
population is a ‘condition sine qua non’ for the diagnosis of AMI. The
vastmajority of cTn assays run on automated laboratory platforms in
Europe are sensitive cTn or hs-cTn, while, e.g. the fourth generation
cTnT, a conventional cTn assay, is still used inmany institutions in the
USA.4,19,24 In addition, many point-of care assays used worldwide
also cannot be considered sensitive or high-sensitivity.21–24
Data from several large multicentre studies have consistently
shown that sensitive cTn and hs-cTn assays increase the accuracy
of the diagnosis of AMI at the time of presentation to the ED.7–23
The benefit observed for sensitive cTn and hs-cTn assays was most
pronounced in patients presenting early after chest pain onset and
could be established also in challenging subgroups such as elderly
patients or patients with pre-existing coronary artery disease.12,13
The use of sensitive cTn or hs-cTn assays allows a more rapid
rule-in and rule-out. While both sensitive cTn and hs-cTn assays
are clearly superior to conventional cTn assays, it is currently still
unknown and a topic of on-going research whether and to what
extent the useof hs-cTn assays provides a clinicallymeaningful advan-
tage with compared with the use of sensitive cTn assays.
Concerns and pitfalls with
high-sensitivity cardiac troponin
While hs-cTn assays have been introduced into clinical practice in
Europe and many other countries (hs-cTnT, Roche in 2010; hs-cTnI,
Abbott in 2013), these assays still await approval for clinical use in
the USA. Most concerns regarding the introduction of hs-cTn assays
including the increased detection of patients with cardiomyocyte
damage from causes other than AMI are in fact concerns to use the
99th percentile.2–5,23,24
It is important to highlight a potential iatrogenic pitfall: levels of cTn
have been reported in mg/L in the last two decades. Despite certain
analytical differences among cTn assays, cardiologists and ED physi-
cians have learned that cTn levels of e.g. 5 or 10 mg/L occur very
rarely and are almost always due to very large AMIs. Now experts
have begun to advocate to report levels of cTn if measured with a
hs-cTn assay in ng/L in order to avoid errors associated with deci-
mals.2,19 This would mean that a normal level of hs-cTn would be
reported as e.g. 5 ng/L rather than 0.005 mg/L and a large AMI
would be reported as e.g. 5000 ng/L rather than 5 mg/L. This transi-
tion obviously requires extensive communication between labora-
tory experts and clinicians in each hospital in order to avoid
iatrogenic harm due to incorrect interpretation of hs-cTn results.
High-sensitivity cardiac troponin:
timing of serial measurements and
the ESC guidelines
Due to the higher sensitivity for the detection ofAMI at presentation,
the time interval to the secondmeasurement of hs-cTn can be signifi-
cantly shortened with the use of hs-cTn assays (Figures 1 and 2).1–5
This is the main clinical advantage of these assays and may result in
substantial reduction in time to decision and therefore total treat-
ment costs in the ED.1–5 While the ESC guidelines use the term
hs-cTnwhen referring to theoptionof using a 3 h rule-out protocol,5
it is very likely that the 3 h rule-out protocol also can be safely applied
with at least some sensitive cTn assays, as the reference study used to
document the safetyof the novel approachused a sensitive cTn (not a
hs-cTn) assay.15 As shown in Figure 1, the 3 h rule-out protocol is not
based on hs-cTn levels only, but also requires patients to be pain-free
and to have a GRACE score below 140.5 In addition, the ESC guide-
lines for the first time highlight the time since chest pain onset as a
modifier. The onset of chest pain in patients with AMI is considered
the onset of cardiomyocyte damage and therefore the release of cTn
into the circulation. In patients who provide a precise estimate of the
onset of acute chest pain, the time interval from chest pain onset to
blood sampling can help interpret cTn findings: AMI may be safely
ruled out without a second measurement once hs-cTn levels are
normal in a patient presenting with a chest pain onset .6 h prior
to ED presentation, so the second cTn draw could be restricted to
patientswith chest painonset,6 horpatients inwhomthis informa-
tion cannot be reliably obtained.5 Although this concept is very
appealing, it should only be applied cautiously and still requires pro-
spective testing. Regarding the rule-in of AMI, a significant rise and/or
fall in cTn is an important criterium to differentiateAMI from chronic
causes of cardiomyocyte injury.2,5
Rapid rule-out and rule-inprotocols
It is a matter of on-going research whether it is possible to safely and
reliable rule-out and rule-in AMI even earlier as the ESC 3 h rule-out
protocol.25–35 Data from large observational multicentre studies
showed an excellent performance of 2 h rule-out protocols that
combine hs-cTn values with clinical information,7–9 but also for a
1 h rule-out and rule-in protocol exclusively based on hs-cTnT
values.10 This approach maximizes the use of the diagnostic
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information included in hs-cTn values by combining two different
assay-specific cut-off values for rule-out and rule-in with absolute
changes within the first hour after presentation.22 This innovative
approach should only be considered for clinical use after successful
external validation. Further highlighting the diagnostic value of inter-
preting hs-cTn concentrations as quantitative values (Figure 3),28 data
from two independent large studies have shown that very lowhs-cTn
levels (e.g. levels belowthe limit of detectionof thehs-cTnTassayson
their own) have a very high negative predictive value of about 99% for
the presence of AMI and may obviate the need for serial testing in
selected patients.24,26,33
Unstable angina in the
high-sensitivity cardiac
troponin era
Some expert had hypothesized that the diagnosis of UA would dis-
appear with the clinical introduction of hs-cTn assays.2 While the
condition currently termed UA may not disappear, the available
data suggest that our current classification scheme that unifies UA
together with AMI as ACS should be reconsidered. By increasing
the detection of patients with small AMIs which were previously in-
correctly classified as UA, the clinical introduction of hs-cTn assays
results in a modest increase in the incidence of AMI and a reciprocal
modest decrease in the incidence of UA.27 In marked contrast to
patients with AMI and similar to patients with non-cardiac causes
of acute chest pain, most patients with UA do not exhibit hs-cTn
changes (Figure 4).29 This indicates the absence of distal coronary
embolization of the culprit lesion as a key differentiating patho-
physiological feature between UA and AMI. When compared with
NSTEMI, also the risk of death is substantially lower in UA, as seem
to be the benefit from early revascularization and aggressive anti-
platelet therapy.30 These observations combined suggest that in
the hs-cTn era UA may well be better placed as a subgroup of
severe stable CAD rather than together with AMI.27–30
Figure2 The use of sensitive or high-sensitivity cardiac troponin
((h)s-cTn) allows more rapid rule-out and more rapid rule-in.
Rule-in of acute myocardial infarction (AMI) can be at presentation
(0 h) in patients with unequivocal ST-elevations, at 1 h in patients
with elevations in cardiac troponin (cTn) in the measurement per-
formed at presentation (turn-around time is around 1 h in most
hospitals) but only at 7 h if the first cTn is normal and the elevation
in cTn becomes apparent only at the second measurement per-
formed after 6 h. Rule-out requires a normal second cTn level
and therefore 7 h. According to the 2011 ESC NSTEMI guidelines,
AMI canbe reliably ruled-out at4 h if a (h)s-cTnassay is used.Recent
research has indicated that (h)s-cTn assays may allow even earlier
rule-out and rule-in if assay-specific algorithms are used or if
applied in combination with copeptin.
Figure 1 Algorithm for the use of high-sensitivity cardiac troponin levels suggested in the 2011 ESC NSTEMI guidelines (adopted from ref. 3).
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Alternative biomarkers reflecting
cardiomyocyte damage: heart-type
fatty-acid binding protein
Heart-type fatty acid-binding protein (h-FABP), a small soluble cyto-
solic protein involved in the transportation of long-chain fatty acids
into the cardiomyocyte, is released rapidly into the circulation in
response to cardiomyocyte injury. Due to its solubility and small
size (15 kDa), h-FABP can be released more rapidly than structurally
bound molecules like cTns.
Thus, h-FABP is regarded as an early sensitivemarker of AMI.35–37
Most of the promising data regarding the potential clinical value of
h-FABP were obtained prior the clinical introduction of hs-cTn
assays. When used on top of hs-cTnT, h-FABP did not seem not
provide relevant added diagnostic value in consecutive patients.
Ongoing research is therefore focusing on the use of h-FABP in
patients presenting very early (,1–2 h since chest pain onset).
Biomarkers reflecting endogenous
stress: copeptin
Copeptin, the c-terminal part of the vasopressin prohormone, is
secreted stochiometrically with arginin–vasopressin from the neu-
rohypophysis and seems to quantify the individual endogenous
stress level and also the mortality risk in multiple medical conditions
including AMI.31–34 As endogenous stress is present already at
the onset of AMI, copeptin appears to be able to identify AMI
very early after symptom onset, even when cTn is still negative
(Figure 5).31–34,38–41 As the time course of endogenous stress and
detectable cardiomyocyte damage seems to be reciprocal, copeptin
seems to be the ideal marker to compensate for the sensitivity deficit
of conventional cTn assays in early presenters. When used in con-
junction with conventional fourth generation cTnT, the added
value of copeptin regarding diagnostic accuracy already at presenta-
tion was substantial.31,32 The added value of copeptin when used
Figure 3 Cardiac troponin (cTn) should be interpreted as a quantitative marker of cardiomyocyte injury. In patients presenting with acute chest
pain, the lower the level, the lower the likelihood and the higher the negative predictive value (NPV) for the presence of acutemyocardial infarction
(AMI). Thereby, the differential diagnosis is broad. In contrast, the higher the level, the higher the likelihood and the higher the positive predictive
value (PPV) for the presence of AMI. The differential diagnosis is much smaller. Importantly, mild elevations of cTn with levels just above the 99th
percentile have a broad differential diagnosis and therefore a rather low PPV for AMI of only 50%. Levels of hs-cTnT are given as mg/L.
Figure 4 Changes of high-sensitivity cardiac troponin within the
first hour after presentation according to the adjudicated final diag-
nosis as surrogate measures to quantify the extent of acute cardio-
myocyte injury that occurred in the preceding hours. Frequency
histograms of changes within the first hour in ng/L for Roche high-
sensitivity cardiac troponin T. Adapted from ref. 29.
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in combination with sensitive cTnI or hs-cTnT seems to be
smaller.31–34,38–41 The concept in which copeptin seems to have
the greatest appeal to clinicians is its use within a dual-marker strategy
for very early rule-out ofAMI: Patientswith acute chest pain presenting
to the ED with initial negative values (below the 99th percentile) of
either sensitive cTn or hs-cTn and also low levels of copeptin (e.g.
,10 pmol/L) do have a very high negative predictive value (around
99%)forAMIandseemtobeappropriatecandidates forrapiddischarge
from the ED without the need for serial cTn testing. In fact, a recent
large multicentre randomized controlled study evaluating the safety
and efficacy of this approach when compared with standard of care
(second cTn measurement after 3–6 h) confirmed this concept.42
Other complimentary prognostic
biomarkers
Natriuretic peptides, midregional pro-adrenomedullin, and GDF-15
are powerful predictors of mortality in patients with suspected or
established ACS, but do not seem to provide added diagnostic infor-
mation.43–47 It is currently unclear how the pathophysiological
signals quantified by these different markers (e.g. haemodynamic
cardiac stress in the case of natriuretic peptides) could be best
used clinically, in order to mitigate the high mortality risk identified
in patients with high levels of these markers.
Biomarkers associated with plaque
instability
As inflammation plays a key role in atherosclerotic plaque formation,
plaque destabilization, and plaque disruption, and in ACS plaque
rupture invariably precedes cardiomyocyte damage by minutes to
potentially hours, biomarkers of plaque instability are logical candi-
dates for early AMI markers.48,49 Unfortunately, recent studies
have consistently shown that at least when measured with currently
available assays markers of plaque instability including myeloperoxi-
dase, myeloid-related protein 8/14, pregnancy-associated plasma
protein-A, and C-reactive protein have very low diagnostic accuracy
and therefore are not helpful in the early diagnosis of AMI.48,49
In conclusion, hs-cTnmeasured at presentation and after 3 h form
the new standard of care since 2011. Likely, even more rapid hs-cTn
protocols with or without the additional use of copeptin will be the
strategies of the future.
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